Acute central nervous system complications and ammonium levels in adult patients with acute lymphoblastic leukemia receiving l-asparaginase

References

• Couturier MA, Huguet F, Chevallier P, et al. Cerebral venous thrombosis in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma during induction chemotherapy with l-asparaginase: the GRAALL experience. Am J Hematol. 2015;90:986–991.
   PubMed Web of Science ®Google Scholar
• DeAngelo DJ, Stevenson KE, Dahlberg SE, et al. Long-term outcome of a pediatric-inspired regimen used for adults aged 18–50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2015;29:526–534.
   PubMed Web of Science ®Google Scholar
• Parasole R, Petruzziello F, Menna G, et al. Central nervous system complications during treatment of acute lymphoblastic leukemia in a single pediatric institution. Leuk Lymphoma. 2010;51:1063–1071.
   PubMed Web of Science ®Google Scholar
• Baytan B, Evim MS, Guler S, et al. Acute central nervous system complications in pediatric acute lymphoblastic leukemia. Pediatr Neurol. 2015;53:312–318.
   PubMed Web of Science ®Google Scholar
• Fleischhack G, Solymosi L, Reiter A, et al. Imaging methods in diagnosis of cerebrovascular complications with l-asparaginase therapy. Klin Padiatr. 1994;206:334–341.
   PubMed Web of Science ®Google Scholar
• Priest JR, Ramsay NK, Steinherz PG, et al. A syndrome of thrombosis and hemorrhage complicating l-asparaginase therapy for childhood acute lymphoblastic leukemia. J Pediatr. 1982;100:984–989.
   PubMed Web of Science ®Google Scholar
• Leonard JV, Kay JD. Acute encephalopathy and hyperammonaemia complicating treatment of acute lymphoblastic leukaemia with asparaginase. Lancet. 1986;1:162–163.
   PubMed Web of Science ®Google Scholar
• Steiner M, Attarbaschi A, Kastner U, et al. Distinct fluctuations of ammonia levels during asparaginase therapy for childhood acute leukemia. Pediatr Blood Cancer. 2007;49:640–642.
   PubMed Web of Science ®Google Scholar
• Heitink-Polle KM, Prinsen BH, de Koning TJ, et al. High incidence of symptomatic hyperammonemia in children with acute lymphoblastic leukemia receiving pegylated asparaginase. JIMD Rep. 2013;7:103–108.
   PubMedGoogle Scholar
• Piccin A, Dossi RC, Cassibba V, et al. Anti-thrombin-III reduction and posterior reversible encephalopathy syndrome (PRES) in acute lymphoblastic leukaemia (ALL). New insight into PRES pathophysiology. Ann Hematol. 2012;91:1153–1155.
   PubMed Web of Science ®Google Scholar
• Frantzeskaki F, Rizos M, Papathanassiou M, et al. l-Asparaginase fatal toxic encephalopathy during consolidation treatment in an adult with acute lymphoblastic leukemia. Am J Case Rep. 2013;14:311–314.
   PubMedGoogle Scholar
• Nussbaum V, Lubcke N, Findlay R. Hyperammonemia secondary to asparaginase: a case series. J Oncol Pharm Pract. 2016;22:161–164.
   PubMedGoogle Scholar
• Miller HK, Salser JS, Balis ME. Amino acid levels following l-asparagine amidohydrolase (EC.3.5.1.1) therapy. Cancer Res. 1969;29:183–187.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2008.
   Google Scholar
• Chalandon Y, Thomas X, Hayette S, et al. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood. 2015;125:3711–3719.
   PubMed Web of Science ®Google Scholar
• Thomas DA, O’Brien S, Cortes J, et al. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood. 2004;104:1624–1630.
   PubMed Web of Science ®Google Scholar
• Conter V, Valsecchi MG, Buldini B, et al. Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis. Lancet Haematol. 2016;3:e80–e86.
   PubMed Web of Science ®Google Scholar
• Maury S, Chevret S, Thomas X, et al. Rituximab in B-lineage adult acute lymphoblastic leukemia. N Engl J Med. 2016;375:1044–1053.
   PubMed Web of Science ®Google Scholar
• Dinndorf PA, Gootenberg J, Cohen MH, et al. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist. 2007;12:991–998.
   PubMed Web of Science ®Google Scholar
• Jorck C, Kiess W, Weigel JF, et al. Transient hyperammonemia due to l-asparaginase therapy in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma. Pediatr Hematol Oncol. 2011;28:3–9.
   PubMed Web of Science ®Google Scholar
• Hough R, Rowntree C, Goulden N, et al. Efficacy and toxicity of a paediatric protocol in teenagers and young adults with Philadelphia chromosome negative acute lymphoblastic leukaemia: results from UKALL 2003. Br J Haematol. 2016;172:439–451.
   PubMed Web of Science ®Google Scholar
• Rytting ME, Thomas DA, O'Brien SM, et al. Augmented Berlin-Frankfurt-Munster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Cancer. 2014;120:3660–3668.
   PubMed Web of Science ®Google Scholar
• O’Brien S, Thomas DA, Ravandi F, et al. Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia. Cancer. 2008;113:2097–2101.
   PubMed Web of Science ®Google Scholar
• Aldoss I, Douer D, Behrendt CE, et al. Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia. Eur J Haematol. 2016;96:375–380.
   PubMed Web of Science ®Google Scholar
• Kwan L, Wang C, Levitt L. Hyperammonemic encephalopathy in multiple myeloma. N Engl J Med. 2002;346:1674–1675.
   PubMed Web of Science ®Google Scholar
• Mitchell RB, Wagner JE, Karp JE, et al. Syndrome of idiopathic hyperammonemia after high-dose chemotherapy: review of nine cases. Am J Med. 1988;85:662–667.
   PubMed Web of Science ®Google Scholar
• Davies SM, Szabo E, Wagner JE, et al. Idiopathic hyperammonemia: a frequently lethal complication of bone marrow transplantation. Bone Marrow Transplant. 1996;17:1119–1125.
   PubMed Web of Science ®Google Scholar
• Liaw CC, Wang HM, Wang CH, et al. Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion of 5-fluorouracil with the complication of dehydration and infection. Anticancer Drugs. 1999;10:275–281.
   PubMed Web of Science ®Google Scholar
• Lewis C, Deshpande A, Tesar GE, et al. Valproate-induced hyperammonemic encephalopathy: a brief review. Curr Med Res Opin. 2012;28:1039–1042.
   PubMed Web of Science ®Google Scholar
• Hwang TL, Yung WK, Estey EH, et al. Central nervous system toxicity with high-dose Ara-C. Neurology. 1985;35:1475–1479.
   PubMed Web of Science ®Google Scholar
• Gokbuget N, Hoelzer D. High-dose methotrexate in the treatment of adult acute lymphoblastic leukemia. Ann Hematol. 1996;72:194–201.
   PubMed Web of Science ®Google Scholar
• Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60:715–735.
   PubMed Web of Science ®Google Scholar
• Haberle J. Clinical practice: the management of hyperammonemia. Eur J Pediatr. 2011;170:21–34.
   PubMed Web of Science ®Google Scholar
• van der Sluis IM, Vrooman LM, Pieters R, et al. Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation. Haematologica. 2016;101:279–285.
   PubMed Web of Science ®Google Scholar
• Pieters R, Hunger SP, Boos J, et al. l-Asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer. 2011;117:238–249.
   PubMed Web of Science ®Google Scholar
• Douer D, Yampolsky H, Cohen LJ, et al. Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood. 2007;109:2744–2750.
   PubMed Web of Science ®Google Scholar